Eitner F, Schulze M, Brunkhorst R, Koch K M, Floege J
Division of Nephrology, Medical School, Hannover, Germany.
J Am Soc Nephrol. 1994 Dec;5(6):1400-6. doi: 10.1681/ASN.V561400.
Immunoglobulin A (IgA)-fibronectin complexes have been proposed as specific serologic markers of IgA nephropathy. They have been detected by the use of ELISA composed of an immobilized antifibronectin antibody (or albumin as a negative control) and an enzyme-conjugated anti-IgA antibody (antifibronectin capture assay). By the use of this type of assay, plasma samples from 32 normal controls, 38 IgA nephropathy patients, and 81 patients with other types of glomerulonephritis were analyzed. Extinction values in IgA nephropathy patients were higher (P = 0.06) than in patients with other glomerulonephritis types and significantly higher than in normals. Markedly lower values were obtained when the plates were coated with albumin. However, when the antifibronectin antibody was replaced by normal IgG or F(ab')2 fragments, almost identical extinctions were measured. The use of different antifibronectin antibodies, IgG, ELISA plates, or blocking regimens did not modify these results. Extinction values could not be suppressed by the addition of exogenous fibronectin. Similar extinctions were observed when plasma samples were replaced by physiologic concentrations of fibronectin-free IgA. Extinction values measured in the plasma samples correlated significantly with IgA concentrations in plasma as analyzed by nephelometry. A collagen binding assay, a second type of assay used to measure IgA-fibronectin complexes, also allowed the detection of fibronectin-free IgA, and again, extinctions measured in plasma could not be suppressed by exogenous fibronectin. In conclusion, both antifibronectin capture ELISA and collagen binding assays do not specifically detect only IgA-fibronectin complexes, but also total plasma IgA, which is frequently, but nonspecifically, elevated in IgA nephropathy.(ABSTRACT TRUNCATED AT 250 WORDS)
免疫球蛋白A(IgA)-纤连蛋白复合物已被提出作为IgA肾病的特异性血清学标志物。它们通过使用由固定化抗纤连蛋白抗体(或白蛋白作为阴性对照)和酶联抗IgA抗体组成的ELISA检测(抗纤连蛋白捕获试验)。通过使用这种类型的试验,分析了32名正常对照、38名IgA肾病患者和81名其他类型肾小球肾炎患者的血浆样本。IgA肾病患者的吸光度值高于其他类型肾小球肾炎患者(P = 0.06),且显著高于正常对照。当平板用白蛋白包被时,得到的值明显更低。然而,当抗纤连蛋白抗体被正常IgG或F(ab')2片段取代时,测得的吸光度几乎相同。使用不同的抗纤连蛋白抗体、IgG、ELISA平板或封闭方案并未改变这些结果。添加外源性纤连蛋白不能抑制吸光度值。当血浆样本被无纤连蛋白的生理浓度IgA取代时,观察到类似的吸光度。血浆样本中测得的吸光度值与通过散射比浊法分析的血浆中IgA浓度显著相关。用于测量IgA-纤连蛋白复合物的第二种试验,即胶原结合试验,也能检测无纤连蛋白的IgA,并且血浆中测得的吸光度同样不能被外源性纤连蛋白抑制。总之,抗纤连蛋白捕获ELISA和胶原结合试验都不能特异性地仅检测IgA-纤连蛋白复合物,还能检测血浆总IgA,而血浆总IgA在IgA肾病中经常但非特异性地升高。(摘要截断于250字)